Overview

Entrectinib is an orally bioavailable tyrosine kinase inhibitor developed to shut down the abnormal signaling produced by NTRK gene fusions, and per FDA labeling it also inhibits ROS1. Because NTRK fusions appear across many unrelated tumor types, this molecule has become a cornerstone of tissue-agnostic oncology, and understanding its molecular logic helps distributors and clinicians explain its value beyond any single indication. The 200 mg capsule presentation covered on this product page is the form many hospital pharmacies request when prescribing against fusion-positive disease.

How NTRK Fusions Deregulate TRK Signaling

Under normal conditions, the TRKA, TRKB and TRKC proteins, encoded by the NTRK1, NTRK2 and NTRK3 genes, sit in the cell membrane and switch on only when neurotrophins bind to them. Certain tumors rearrange these genes so the kinase domain of TRK fuses to an unrelated partner protein. The fusion removes the regulatory segments that normally keep the kinase switched off, producing a receptor that signals without any ligand at all. The resulting cascade flows through the RAS/MAPK, PI3K/AKT and PLC-gamma pathways, driving survival and proliferation commands into the nucleus.

Entrectinib occupies the ATP pocket of these fusion kinases and competes with ATP, so the fusion protein can no longer transfer phosphate groups onto its downstream targets. With phosphorylation halted, the entire oncogenic circuit collapses. The same inhibitory chemistry applies to the ROS1 fusion kinase found in a subset of non-small cell lung cancer, which places entrectinib among the few molecules with documented activity on two distinct fusion-driven axes per its approved labeling.

Why CNS Penetration Shapes Its Clinical Profile

Many kinase inhibitors are excluded from the brain by efflux transporters at the blood-brain barrier, which limits their usefulness against intracranial metastases. Entrectinib was deliberately engineered to cross this barrier, and its labeling reflects central nervous system exposure as a defining pharmacological feature. For fusion-positive patients, whose disease can seed the brain, a systemically active agent that also reaches intracranial lesions changes the practical conversation between oncologists and pharmacists about treatment selection. Prescribing information also notes central nervous system adverse reactions, so neuropsychiatric monitoring forms part of routine pharmacovigilance.

FAQ

Q: Does entrectinib target the TRK protein itself or the fusion partner? A: It targets the kinase domain of TRK proteins. The fusion partner simply keeps the domain abnormally active, so blocking that domain interrupts signaling regardless of which partner gene is involved.

Q: Is entrectinib active against ROS1 fusions as well as NTRK fusions? A: Yes. FDA labeling describes entrectinib as an inhibitor of TRK and ROS1, which is why it is associated with both fusion-positive solid tumors and ROS1-positive metastatic non-small cell lung cancer.

Q: Why does brain penetration matter when sourcing this molecule for hospital customers? A: Fusion-driven tumors can metastasize to the central nervous system, and pharmacy committees frequently compare agents on blood-brain barrier passage, so this property is a genuine procurement discussion point rather than marketing language.